<code id='1E5DEB6FF3'></code><style id='1E5DEB6FF3'></style>
    • <acronym id='1E5DEB6FF3'></acronym>
      <center id='1E5DEB6FF3'><center id='1E5DEB6FF3'><tfoot id='1E5DEB6FF3'></tfoot></center><abbr id='1E5DEB6FF3'><dir id='1E5DEB6FF3'><tfoot id='1E5DEB6FF3'></tfoot><noframes id='1E5DEB6FF3'>

    • <optgroup id='1E5DEB6FF3'><strike id='1E5DEB6FF3'><sup id='1E5DEB6FF3'></sup></strike><code id='1E5DEB6FF3'></code></optgroup>
        1. <b id='1E5DEB6FF3'><label id='1E5DEB6FF3'><select id='1E5DEB6FF3'><dt id='1E5DEB6FF3'><span id='1E5DEB6FF3'></span></dt></select></label></b><u id='1E5DEB6FF3'></u>
          <i id='1E5DEB6FF3'><strike id='1E5DEB6FF3'><tt id='1E5DEB6FF3'><pre id='1E5DEB6FF3'></pre></tt></strike></i>

          00:00
          00:00 00:00 LIVE
          buffering
          Replay
          LIVE
          00:00 / 00:00
          LIVE
          CC
          Opacity :
          Share:
          Close

          explore

          author:focus    - browse:45438
          Allergan, Dom Smith/STAT

          It wasn’t supposed to work out this way for Brent Saunders.

          Four years ago, Saunders was the whiz kid of the pharmaceutical set. At 44, he had created a large pharmaceutical firm, then called Actavis, almost by force of will after engineering more than $100 billion in deals in a two-year span. Then he had swooped in to rescue Botox maker Allergan from the nefarious claws of Valeant Pharmaceuticals, an asset-stripping drug company loved by many on Wall Street but no one with a conscience.

          advertisement

          As CEO, he paired his dealmaking with a boyish charm and a willingness to take on big issues that made him seem like a potential spokesman for the whole industry.

          Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

          GET STARTED Log In

          entertainment